This is of utmost important as patients diagnosed with IDH-mutant grade II gliomas are often younger and delaying their need for radiation and/or chemotherapy leads to improvement in their quality of life and decrease in morbidity, especially given the well-tolerated side effect profile of IDH inhibitors. This evidence concerns the gene IDH1 and glioma.